What is the role of pembrolizumab in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Pembrolizumab, a PD-1 inhibitor, gained approval in 2018 as a first-line treatment option for metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel. Approval was supported by the KEYNOTE-407 study. In the trial, the combination of pembrolizumab plus chemotherapy (carboplatin and paclitaxel or nab-paclitaxel) significantly improved overall survival (OS) compared with chemotherapy alone, at a median of 15.9 months compared with 11.3 months (hazard ratio [HR], 0.64; P = 0.0017). [171]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!